This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meads, M. B. Articles by Dalton, W. S. Search for Related Content PubMed PubMed Citation Articles by Meads, M. B. Articles by Dalton, W. S.

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

Authors' Affiliation: Department of Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Requests for reprints: William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Phone: 813-745-4261; Fax: 813-745-4258; E-mail: William.Dalton{at}moffitt.org.

Abstract

The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of hematopoietic cells. These cells are supported by fibroblast-like bone marrow stromal cells, osteoblasts, and osteoclasts which secrete soluble factors and extracellular matrix proteins that mediate these functions. This rich environment serves as a safe haven not only for normal and malignant hematopoietic cells, but also for epithelial tumor cells that metastasize to bone, offering protection from chemotherapeutic agents by common mechanisms. Soluble factors produced in the bone marrow, such as stromal cell–derived factor-1 and interleukin-6, mediate homing, survival, and proliferation of tumor cells, and integrin-mediated adhesion sequesters tumor cells to this protective niche. Environment-mediated drug resistance includes a combination of soluble factors and adhesion, and can be subdivided into soluble factor–mediated drug resistance and cell adhesion–mediated drug resistance. Because it is induced immediately by the microenvironment and is independent of epigenetic or genetic changes caused by the selective pressure of drug exposure, environment-mediated drug resistance is a form of de novo drug resistance. In this form of drug resistance, tumor cells are transiently and reversibly protected from apoptosis induced by both chemotherapy and physiologic mediators of cell death. This protection allows tumor cells to survive the insult of chemotherapy, leading to minimal residual disease, and thereby increases the probability for the development of acquired drug resistance.

This article has been cited by other articles:

				B. Nervi, P. Ramirez, M. P. Rettig, G. L. Uy, M. S. Holt, J. K. Ritchey, J. L. Prior, D. Piwnica-Worms, G. Bridger, T. J. Ley, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 Blood, June 11, 2009; 113(24): 6206 - 6214. [Abstract] [Full Text] [PDF]

				M. Niedermeier, B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood, May 28, 2009; 113(22): 5549 - 5557. [Abstract] [Full Text] [PDF]

				M. Vogler, M. Butterworth, A. Majid, R. J. Walewska, X.-M. Sun, M. J. S. Dyer, and G. M. Cohen Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia Blood, April 30, 2009; 113(18): 4403 - 4413. [Abstract] [Full Text] [PDF]

				K. H. Shain, D. N. Yarde, M. B. Meads, M. Huang, R. Jove, L. A. Hazlehurst, and W. S. Dalton {beta}1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation Cancer Res., February 1, 2009; 69(3): 1009 - 1015. [Abstract] [Full Text] [PDF]

				T. M. Garcia-Bates, S. H. Bernstein, and R. P. Phipps Peroxisome Proliferator-Activated Receptor {gamma} Overexpression Suppresses Growth and Induces Apoptosis in Human Multiple Myeloma Cells Clin. Cancer Res., October 15, 2008; 14(20): 6414 - 6425. [Abstract] [Full Text] [PDF]